The role of combination therapy with corticosteroids and long-acting β₂-agonists in the prevention of exacerbations in COPD

References

• AlsaeediASinDDMcAlisterFA2002The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trialsAm J Med113596512106623
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society2005Standards for the diagnosis and management of patients with COPDAccessed 22 January 2006 URL: http://www.thoracic.org
   Google Scholar
• BaraniukJNAliMBrodyD1997Glucocorticosteroids induce β2-adrenergic receptor function in human nasal mucosaAm J Respir Crit Care Med155704109032216
   PubMed Web of Science ®Google Scholar
• BarnesPJ2000Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med161342410673166
   PubMed Web of Science ®Google Scholar
• BarnesPJ2004Corticosteroid resistance in airway diseaseProc Am Thorac Soc1264816113444
   PubMedGoogle Scholar
• BarnesNCQiuYSPavordID2006Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung diseaseAm J Respir Crit Care Med1737364316424444
   PubMed Web of Science ®Google Scholar
• CalverleyPM2000Inhaled corticosteroids are beneficial in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med161341210673165
   PubMed Web of Science ®Google Scholar
• CalverleyPM2004Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary diseaseProc Am Thorac Soc1121416113424
   PubMedGoogle Scholar
• CalverleyPMBoonsawatWCsekeZ2003bMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J22912914680078
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJ2003aTRial of Inhaled STeroids ANd long-acting β2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet3614495612583942
   PubMed Web of Science ®Google Scholar
• CazzolaM2006Application of number needed to treat (NNT) as a measure of treatment effect in respiratory medicineTreat Respir Med5798416512688
   PubMedGoogle Scholar
• CazzolaMDahlR2004Inhaled combination therapy with long acting β2-agonists and corticosteroids in stable COPDChest1262203715249466
   PubMed Web of Science ®Google Scholar
• CazzolaMDi MarcoFSantusP2004The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPDPulm Pharmacol Ther1735914643169
   PubMed Web of Science ®Google Scholar
• CazzolaMSalzilloADe GiglioC2005Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniaeRespir Med99663915878482
   PubMed Web of Science ®Google Scholar
• ChanezPVignolaAMO’ShaugnessyT1997Corticosteroid reversibility in COPD is related to features of asthmaAm J Respir Crit Care Med1551529349154853
   PubMed Web of Science ®Google Scholar
• ChapmanKRWalkerLCluleyS2000Improving patient compliance with asthma therapyRespir Med942910714473
   PubMed Web of Science ®Google Scholar
• CouttsJAPGibsonNAPatonJY1992Measuring compliance with inhaled medication in asthmaArch Dis Child6733231575560
   PubMed Web of Science ®Google Scholar
• DahlRGreefhorstLANowakD2002Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1647788411549532
   PubMed Web of Science ®Google Scholar
• de MeloMNErnstPSuissaS2004Inhaled corticosteroids and the risk of a first exacerbation in COPD patientsEur Respir J23692715176681
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikA2002Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax578475212324669
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTAPatelIS2003Longitudinal changes in the nature, severity and frequency of COPD exacerbationsEur Respir J22931614680081
   PubMed Web of Science ®Google Scholar
• DowlingRBJohnsonMColePJ1999Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitroEur Respir J14363910515415
   PubMed Web of Science ®Google Scholar
• EdwardsMRJohnsonMJohnstonSL2006Combination therapy: synergistic suppression of virus induced chemokines in airway epithelial cellsAm J Respir Cell Mol Biol119 [Epub ahead of print]
   Web of Science ®Google Scholar
• EickelbergORothMLorxR1999Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cellsJ Biol Chem2741005109873044
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease2005Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease NHBLI/WHO Workshop ReportAccessed 22 January 2006 URL: http://www.goldcopd.com
   Google Scholar
• HalpinDM2005Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysisInt J Clin Pract5911879416178987
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanD2003The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPDChest1248344312970006
   PubMed Web of Science ®Google Scholar
• HaughneyJGruffydd-JonesK2004Patient-centred outcomes in primary care management of COPD - what do recent clinical trial data tell us?Primary Care Resp J1318597
   PubMedGoogle Scholar
• JonesPW2004Clinical effects of inhaled corticosteroids in chronic obstructive pulmonary diseaseProc Am Thorac Soc11677016113430
   PubMedGoogle Scholar
• JonesPWWillitsLRBurgePS2003Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbationsEur Respir J21687312570111
   PubMed Web of Science ®Google Scholar
• KiriVAPrideNBSorianoJB2005Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time biasAm J Respir Crit Care Med172460415901610
   PubMed Web of Science ®Google Scholar
• KornSHJerreABrattsandR2001Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cellsEur Respir J171070711491146
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanD2002Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16610849112379552
   PubMed Web of Science ®Google Scholar
• MakJCNishikawaMShirasakiH1995Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivoJ Clin Invest96991067615841
   PubMed Web of Science ®Google Scholar
• ManSFSinDD2005Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?Drugs655799115748094
   PubMed Web of Science ®Google Scholar
• MartinezFJAnzuetoA2005Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitisAm J Med118Suppl 7AS3944
   Google Scholar
• NanniniLCatesCJLassersonTJ2004Combined corticosteroid and long-acting β-agonist in one inhaler for chronic obstructive pulmonary diseaseCochrane Database Syst Rev3CD00379415266502
   PubMed Web of Science ®Google Scholar
• Niewoehn2004Interventions to prevent chronic obstructive pulmonary disease exacerbationsAm J Med117Suppl 12AS418
   Google Scholar
• PangLKnoxAJ2000Synergistic inhibition by β2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth-muscle cellsAm J Respir Cell Mol Biol23798510873156
   PubMed Web of Science ®Google Scholar
• PangLKnoxAJ2001Regulation of TNF-β-induced eotaxin release from cultured human airway smooth muscle cells by β2-agonists and corticosteroidsFASEB J15261911149914
   PubMed Web of Science ®Google Scholar
• PauwelsRCalverleyPBuistAS2004COPD exacerbations: the importance of a standard definitionRespir Med989910714971871
   PubMed Web of Science ®Google Scholar
• RabeK2003Combination therapy for chronic obstructive pulmonary disease: one size fits all?Eur Respir J22874514680071
   PubMed Web of Science ®Google Scholar
• RennardSI2004Treatment of stable chronic obstructive pulmonary diseaseLancet36479180215337408
   PubMed Web of Science ®Google Scholar
• SeemungalTHarper-OwenRBhowmikA2001Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16416182311719299
   PubMed Web of Science ®Google Scholar
• SeetoLJBurgessJKJohnsonPR2003Effect of fluticasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD) [abstract]Am J Respir Crit Care Med167A318
   Google Scholar
• SinDDWuLAndersonJAAnthonisenNR2005Inhaled corticosteroids and mortality in chronic obstructive pulmonary diseaseThorax60992716227327
   PubMed Web of Science ®Google Scholar
• SolèrM2005Modulation of airway inflammation to prevent exacerbations of COPDEur Respir Rev147882
   Google Scholar
• StockleyRAChopraNRiceL2006Addition of salmeterol to existing treatment in patients with COPD: a 12 month studyThorax61122816443706
   PubMed Web of Science ®Google Scholar
• SuissaS2006Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med173842616439716
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J21748112570112
   PubMed Web of Science ®Google Scholar
• TsangKWRutmanATanakaE1994Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitroEur Respir J71746537828679
   PubMed Web of Science ®Google Scholar
• TseRMarroquinBADorscheidDR2003β-adrenergic agonists inhibit corticosteroid-induced apoptosis of airway epithelial cellsAm J Physiol Lung Cell Mol Physiol285L39340412730077
   PubMed Web of Science ®Google Scholar
• van der ValkPMonninkhofEvan der PalenJ2002Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med16613586312406823
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensE2005Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J262142216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensE2006Effects of tiotropium with and without formoterol on airflow obstruction and resting hyper-inflation in patients with COPDChest1295091716537846
   PubMed Web of Science ®Google Scholar
• WilsonR1991Infections of the airwaysCurr Opin Infect Dis416677
   Web of Science ®Google Scholar
• WoutersEFMPostmaDSFokkenstB2005Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes an immediate and sustained disease deterioration: a randomised controlled trialThorax60480715923248
   PubMed Web of Science ®Google Scholar